LLY News and Press, Eli Lilly and Company From 04/16/24

2024-04-16 16:36:58 ET Summary Inadequate pension savings and ever-increasing longevity is threatening investors' well-being in retirement. Planning for retirement is a life-long process, the earlier you start the better. This allows you to benefit from the full power of compoundi...

2024-04-16 16:24:42 ET Summary The healthcare sector is overvalued by 14% based on 11-year averages. Healthcare providers are not far from their valuation baseline, while the most overvalued subsector is healthcare equipment. Fast facts on Fidelity MSCI Health Care Index ETF, ...

2024-04-16 12:38:35 ET More on Lexaria Bioscience Corp. Lexaria to test DehydraTECH GLP-1 product for weight loss, diabetes Lexaria slips despite FDA nod to test blood pressure drug Seeking Alpha’s Quant Rating on Lexaria Bioscience Corp. Historical ea...

2024-04-16 12:23:16 ET More on Bayer, Bayer AG, etc. Bayer AG (BAYZF) Q4 2023 Earnings Call Transcript Bayer Fiscal 2023 Results: Mr. Anderson, Deliver Us From Bad News (Rating Downgrade) Bayer: Long-Term Upside After The Dividend Cut Google, Bayer in pact fo...

2024-04-16 12:22:50 ET More on rare disease pharmas/biotechs Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy Sarepta Therapeutics: Another 'Hold' Call Ahead Of Some Key Catalysts Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success...

Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement PR Newswire INDIANAPOLIS , April 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2024 financial results on April 30, 2024 ...

2024-04-15 16:08:10 ET Summary Given the huge and growing GLP-1 weight loss market, recent trial data from Viking Therapeutics could make it a potential acquisition target for a larger concern. While many bigger pharma names might desire entry into the huge GLP-1 weight loss marke...

2024-04-14 17:56:08 ET More on Boston Scientific, CONMED, etc. ResMed: Not A Sleeper Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash Boston Scientific: The Market's Newest Mega-Cap Needs A Breather Mizuho sees ResMed as 'overwhelming ben...

2024-04-13 08:47:00 ET Does a 100% return in less than seven years sound pretty good? Most investors would probably say so. But which stocks are good candidates to achieve such a gain? Three Motley Fool contributors think they've found magnificent stocks that could double or more by 203...

2024-04-12 13:17:44 ET Short percentage in S&P 500’s healthcare companies surged in the end of March from February, as the life science tools and services sub-sector saw a jump in short interest from the previous month.... Read the full article on Seeking Alpha For fu...